Company profile
Sonoma Pharmaceuticals, Inc.
NASDAQ: SNOA · Healthcare · Drug Manufacturers - Specialty & Generic
#550 of 1,422 Healthcare companies by revenue74th-percentile growth
EA Score
60CFH 43DQ 83GM 69SS 47
v0.1 · 65/100 weight · provisional
↑ disclosure history, listing tenure · ↓ Piotroski F, workforce scale
Methodology →Revenue TTM
$19.5M
Rev growth YoY (TTM)
+36.7%
Net income (FY)
-$3.2M
Employees
10
as of 2026-08-25
Market cap
$2.3M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$19.5M$19.5M2026
Net income-$3.2M-$3.2M2026
Operating income-$2.5M-$2.5M2026
Total assets$14.0M$14.0M2026
Liabilities$10.9M$10.9M2026
Equity$3.1M$3.1M2026
Revenue trend
FY2020 – FY2026 · USD
FY20
FY20
FY21
FY22
FY23
FY24
FY25
FY26
Revenue by segment
Filed disclosures · FY2026
By product
Human Care91%
Animal Care9%
By geography
Not disclosed.
The read
What is Sonoma Pharmaceuticals, Inc.’s revenue?
Sonoma Pharmaceuticals, Inc. booked $19.5M in FY2026 revenue, growing 37% year over year — faster than most Healthcare companies we track, at a -16.3% net margin.
Peers · Healthcare
Immix Biopharma, Inc.49DSpectral AI, Inc.39DCarisma Therapeutics, Inc.——Avem Health Partners, Inc.——cbdMD, Inc.49DPrecision Optics Corporation, Inc.61CNeighbors
Cherokee →Key facts
CEOAmy Trombly
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersWoodstock, GA
ExchangeNASDAQ: SNOA
Employees10
IPO date2007-01-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.